[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alopecia-areata--ophiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alopecia-areata--ophiasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100649297","serum-ferroptosis-biomarkers-gpx4-mda-in-alopecia-areata-100649297",false,"NCT07733063","Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata","Evaluation of Serum Ferroptosis Biomarkers (GPX4 and MDA) and Their Relationship With Disease Stage, Clinical Severity, and Trichoscopic Findings in Patients With Alopecia Areata","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years.\n* Formally diagnosed with Alopecia Areata based on clinical and trichoscopic examination.\n* Healthy volunteers with no personal or family history of alopecia or any systemic inflammatory\u002Fautoimmune conditions (for the healthy control group).\n* Patients who have provided written informed consent before any study-related procedures.\n\nExclusion Criteria:\n\n* Use of topical corticosteroids, intralesional steroid injections, or topical calcineurin inhibitors within the last 1 month.\n* Use of systemic immunosuppressive therapies, systemic corticosteroids, or JAK inhibitors within the last 3 months.\n* Presence of any other co-existing active autoimmune or inflammatory skin diseases (e.g., Psoriasis, Vitiligo, or active autoimmune thyroiditis with elevated TSH levels).\n* History of malignancy, active severe infection, chronic hepatic failure, or chronic renal failure.\n* Pregnancy or lactation.\n* History of heavy smoking or uncontrolled\u002Fregular use of antioxidant or vitamin supplements (e.g., Vitamin E, Vitamin C, CoQ10, NMN, resveratrol).",true,"ALL","18 Years","65 Years",{"count":21,"type":22},156,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the potential role of the ferroptosis pathway in the pathogenesis and clinical course of Alopecia Areata (AA). Serum concentrations of two key ferroptosis biomarkers-Glutathione Peroxidase 4 (GPX4), a primary antioxidant enzyme protecting against lipid peroxidation, and Malondialdehyde (MDA), a major end-product of lipid membrane damage-will be quantitatively measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits.\n\nA total of 156 participants will be enrolled, consisting of 104 patients diagnosed with Alopecia Areata (subdivided into acute and chronic cohorts) and 52 age- and sex-matched healthy controls. Serum biomarker levels will be statistically compared among the groups to determine their diagnostic value. Furthermore, these biomarker levels will be correlated with clinical disease extension evaluated via the Severity of Alopecia Tool (SALT) score and objective trichoscopic activity findings (such as black dots, yellow dots, and exclamation mark hairs). The ultimate goal of this cross-sectional study is to evaluate whether serum GPX4 and MDA can serve as reliable objective biomarkers for monitoring disease severity, staging, and trichoscopic activity in Alopecia Areata management.The ultimate goal of this cross-sectional study is to evaluate whether serum GPX4 and MDA can serve as reliable objective biomarkers for monitoring disease severity, staging, and trichoscopic activity in Alopecia Areata management.",[26,27,28,29],"Alopecia Areata(AA)","Alopecia Areata","Alopecia Areata (& Ophiasis)","Alopecia",[31,32,33,34],"ferroptosis","alopecia areata","GPX4","MDA","RECRUITING","2026-07-29",{"date":38,"type":39},"2026-07-30","ACTUAL",{"date":41,"type":39},"2026-06-01",{"date":43,"type":22},"2027-01-01",{"name":45,"class":46},"Istanbul Training and Research Hospital","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100622279","phase-4-cyclosporine-or-methotrexate-for-pediatric-alopecia-areata-routine-clinical-care-effectiveness-study-100622279","NCT07381556","Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study","The Effectiveness of Cyclosporine Versus Methotrexate in the Treatment of Pediatric Alopecia Areata in Routine Clinical Care: a Patient Preference Trial","COMPARE","Inclusion criteria\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Age 2-17 years\n* Clinical diagnosis of AA by a certified dermatologist\n* Willingness of participant (in case 12-17 years) and parents to provide informed consent for participation in the study.\n\nExclusion criteria\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion.\n* Patients who are ineligible for the CsA arm (due to contraindications), are automatically included in the MTX arm.\n* Contra-indications CsA:\n\nImpaired kidney function. Poorly controlled hypertension Active infections. Presence of a malignancy. Nephrotic syndrome combined with poorly controlled hypertension, infection or malignancy.\n\nKidney disorders, except in cases of nephrotic syndrome with mild to moderate renal impairment.\n\n* Patients who are ineligible for the MTX arm (due to contraindications), are automatically included in the CsA arm.\n* Contraindications MTX:\n\nConception (both male and female) and lactation Severe kidney or liver dysfunction (fibrosis, cirrhosis) or alcohol abuse Bone marrow hypoplasia, immunodeficiency Anemia, leukopenia, or thrombocytopenia Poor nutritional status (low albumin) Hypersensitivity or allergy to MTX Lung toxicity due to MTX or significant reduction in lung function.","2 Years","17 Years",{"count":59,"type":22},50,"INTERVENTIONAL",[62],"PHASE4","Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata. Eligibility for this treatment, in the Netherlands, requires prior failure of systemic therapies such as cyclosporin or methotrexate. However, the choice between methotrexate and cyclosporin as first-line systemic treatment is not supported by robust comparative studies.\n\nTherefore, the investigators conduct a patient preference trial with a long-term follow-up provided in the Pediatric Systemic Alopecia Areata Registry (STA2R-Pediatric). This study will evaluate the effectiveness of Cyclosporin (CsA) and Methotrexate (MTX) in children and adolescents with moderate-to-severe AA.\n\nObjective(s): To investigate the effectiveness of CsA and MTX in the treatment of children and adolescents with alopecia areata in routine clinical care.\n\nStudy type: This is a prospective, patient preference clinical trial with a duration up to 36 weeks in accordance with the routine clinical care guidelines.\n\nStudy population: This study will include children and adolescents (2-17 years old) diagnosed with AA who start first-line systemic treatment.\n\nMethods: Patients and their parents will choose between CsA and MTX treatment as in routine clinical care, receiving follow-up in accordance with standard clinical practices. The participants will not be randomized. The primary endpoint is the measurement of the Severity of Alopecia Tool (SALT) at 9-months with a secondary endpoint at 24 weeks. SALT scores will be measured by a blinded assessor. The (Children) - Dermatology Life Quality Index ((C)-DLQI) questionnaire will be conducted at each visit (0, 3, 6, 9 months), allowing evaluation of the impact on patients' quality of life.",[26,65,66,67,68,28],"Alopecia Areata (AA)","Alopecia Totalis\u002FUniversalis","Alopecia Universalis (AU)","Alopecia Totalis (AT)",[70,71,72],"Pediatric","Alopecia areata","systemic treatment alopecia areata","2026-01-26",{"date":75,"type":39},"2026-02-02",{"date":77,"type":39},"2025-11-01",{"date":79,"type":22},"2027-11-01",{"name":81,"class":82},"Erasmus Medical Center","OTHER"]